These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29551231)

  • 1. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.
    Quon HC; Ong A; Cheung P; Chu W; Chung HT; Vesprini D; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Loblaw A
    Radiother Oncol; 2018 May; 127(2):206-212. PubMed ID: 29551231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT).
    Alayed Y; Quon H; Ong A; Cheung P; Chu W; Chung H; Vesprini D; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Loblaw A
    Radiother Oncol; 2020 Aug; 149():8-13. PubMed ID: 32416376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial.
    De Cock L; Draulans C; Pos FJ; Isebaert S; De Roover R; van der Heide UA; Smeenk RJ; Kunze-Busch M; van der Voort van Zyp J; de Boer H; Kerkmeijer LGW; Haustermans K
    Radiother Oncol; 2023 Aug; 185():109713. PubMed ID: 37178932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy.
    Elias E; Helou J; Zhang L; Cheung P; Deabreu A; D'Alimonte L; Sethukavalan P; Mamedov A; Cardoso M; Loblaw A
    Radiother Oncol; 2014 Jul; 112(1):83-8. PubMed ID: 25005578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials.
    Alayed Y; Quon H; Cheung P; Chu W; Chung HT; Vesprini D; Ong A; Chowdhury A; Panjwani D; Helou J; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Commisso A; Commisso K; Loblaw A
    Radiother Oncol; 2019 Nov; 140():105-109. PubMed ID: 31265940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results.
    Zilli T; Jorcano S; Bral S; Rubio C; Bruynzeel AME; Oliveira A; Abacioglu U; Minn H; Symon Z; Miralbell R
    Cancer Med; 2020 May; 9(9):3097-3106. PubMed ID: 32160416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.
    Fuller DB; Falchook AD; Crabtree T; Kane BL; Medbery CA; Underhill K; Gray JR; Peddada A; Chen RC
    Eur Urol Oncol; 2018 Dec; 1(6):540-547. PubMed ID: 31158102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy.
    Qi XS; Wang JP; Gomez CL; Shao W; Xu X; King C; Low DA; Steinberg M; Kupelian P
    Radiother Oncol; 2016 Oct; 121(1):113-117. PubMed ID: 27587270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer.
    Katz A; Ferrer M; Suárez JF;
    Radiat Oncol; 2012 Nov; 7():194. PubMed ID: 23164305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinical Trial.
    Iarrobino NA; Gill B; Sutera PA; Kalash R; D' Ambrosio D; Heron DE
    Am J Clin Oncol; 2019 Nov; 42(11):856-861. PubMed ID: 31584457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.
    Johnson SB; Soulos PR; Shafman TD; Mantz CA; Dosoretz AP; Ross R; Finkelstein SE; Collins SP; Suy S; Brower JV; Ritter MA; King CR; Kupelian PA; Horwitz EM; Pollack A; Abramowitz MC; Hallman MA; Faria S; Gross CP; Yu JB
    Radiother Oncol; 2016 Nov; 121(2):294-298. PubMed ID: 27890426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial.
    Wang K; Chen RC; Kane BL; Medbery CA; Underhill KJ; Gray JR; Peddada AV; Fuller DB
    Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1430-1437. PubMed ID: 30056080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.
    Rucinska M; Kieszkowska-Grudny A; Nawrocki S
    Strahlenther Onkol; 2016 Jul; 192(7):449-57. PubMed ID: 27221312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806).
    Isfahanian N; Lukka H; Dayes I; Quan K; Schnarr KL; Douvi G; Goldberg M; Wright J; Swaminath A; Chow T; Diamond K; Cutz JC; Kavsak P; Thabane L; Tsakiridis T
    Clin Genitourin Cancer; 2020 Aug; 18(4):e410-e415. PubMed ID: 32265129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: stereotactic ablative radiotherapy or external beam+high dose rate brachytherapy boost.
    Helou J; Morton G; Zhang L; Deabreu A; D'Alimonte L; Elias E; Musunuru HB; Mamedov A; Ravi A; Chung H; Cheung P; Loblaw A
    Radiother Oncol; 2014 Dec; 113(3):404-9. PubMed ID: 25466371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol.
    Richardson M; Sidhom M; Gallagher S; Grand M; Pryor D; Bucci J; Wilton L; Arumugam S; Keats S; Martin JM
    BMC Cancer; 2018 May; 18(1):588. PubMed ID: 29793444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
    BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
    Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer.
    Poon DMC; Lam D; Wong KCW; Chu CM; Cheung M; Mo F; Suen J; Ng CF; Chan ATC
    Curr Oncol; 2021 Dec; 29(1):27-37. PubMed ID: 35049677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.